KAHF Biotech is Redefining the Future of Cancer Treatment Through Next-Generation Therapeutic Platforms Targeting Aggressive, Metastatic, and Dormant Tumors.

Pioneering a target-centric therapeutic ecosystem to transform cancer treatment across diverse tumor types and disease stages.

.

Dormant Cancer

Dormant cancer cells are tumor cells that lie inactive in the body-often undetectable and resistant to conventional therapies. Though silent, they can awaken months or even years later to cause relapse and metastasis. At KAHF Biotech, we believe targeting these elusive cells is key to achieving long-term remission and true cancer cures.

Metastatic Tumor

Metastatic tumors arise when cancer cells spread from the original tumor to distant organs, forming new, often aggressive growths. These tumors are responsible for the vast majority of cancer deaths and are notoriously difficult to treat. At KAHF Biotech, we are committed to targeting the root drivers of metastasis to stop cancer.

Technologies

At KAHF Biotech, Inc., we leverage a target-centric oncology platform to develop multiple therapeutic and diagnostic modalities, including monoclonal antibodies, antibody-drug conjugates (ADCs), cell therapies, RNA therapeutics, and precision diagnostics. By selectively targeting the biological drivers of tumor progression, metastasis, treatment resistance, and recurrence, we aim to transform the treatment of both solid and hematological malignancies.

.

KAHF Biotech is building a target-centric oncology platform designed to generate multiple therapeutic modalities—including monoclonal antibodies, ADCs, cell therapies, RNA therapeutics, and companion diagnostics—from a single biological discovery.

OUR MISSION

At KAHF Biotech, Inc., we are driven by a simple, yet profound truth: cancer patients deserve more than the silence of being told, “There’s nothing more we can do.” Our name is rooted in the timeless story of KAHF-a story of resilience, refuge, and unwavering faith in the face of great adversity. Just as the youths sought shelter in a cave and were granted protection and time, we strive to offer a refuge for patients and families navigating the storm of cancer.

We believe that every scientific breakthrough is a form of divine timing-that healing comes through both persistence and trust in a higher plan. Our work is more than just medicine; it is a mission to bring hope, strength, and life-saving innovation to those who need it most.

At KAHF Biotech, Inc., we are on a relentless mission to Chase, Capture, and Eliminate metastatic cancer cells. We chase new frontiers in cancer therapy, targeting metastatic disease with cutting-edge research and innovation. We capture cancer with pinpoint accuracy, ensuring our therapies reach the heart of the disease. And, most importantly, we eliminate it-bringing life-saving solutions to those who have run out of options.

Motto: Chase, Capture, Eliminate

KAHF Biotech is in preliminary stage of development. The mission of company is to open a new avenue for treatment and prevention of cancer metastasis. The company’s focus is on Cancer Metastasis Prevention and Elimination.

Mission Statement

Our mission is to establish KAHF Biotech as an industry leader in the development of innovative therapies for cancer treatment, with a particular focus on metastatic disease and aggressive cancers with significant unmet medical need. We are committed to advancing transformative therapeutic approaches that aim to improve patient outcomes, expand treatment possibilities, and bring hope to patients and families facing some of the most challenging forms of cancer.

Vision

Our vision is to become a global leader in cancer therapeutics by revolutionizing the treatment of metastatic and aggressive cancers through the development of impactful, effective, and accessible therapies. We strive to overcome the challenges associated with advanced disease and deliver innovative treatment solutions to patients worldwide, improving survival, quality of life, and long-term outcomes for those facing cancer — especially those who need them most, no matter where they are.

 

OUR SKILLS
Cancer Therapeutic Development and Discovery
Preclinical Development
IND-enabling Studies
Clinical Trials
MSND

Cancer Therapeutic Development Particularly Metastatic and Dormant Cancer Cells

INVESTMENT OPPORTUNITY

KAHF Biotech is advancing a patent-pending therapeutic oncology platform focused on addressing some of the most challenging problems in cancer treatment, including metastasis, therapeutic resistance, and tumor recurrence. We welcome discussions with investors, strategic partners, scientific advisors, and organizations interested in accelerating the development of next-generation cancer therapies.

 

 

KAHF Biotech, Inc.

0
HOURS OF WORK
0
FINISHED WORKS
0
CLIENTS
0
SOCIAL FOLLOWERS

Collaborators

UR Medicine Wilmot Cancer Institute logo featuring a shield crest and the wordmarks, with the motto 'Medicine of the Highest Order'.SinoBiological

The science driving KAHF BIOTECH, INC. is supported through collaborations with leading institutions, including the NCI-designated Wilmot Cancer Institute at the University of Rochester Medical Center and Sino Biological, a global leader in recombinant protein production and antibody development.

PIPELINE

Technologies

Monoclonal Antibody
Antibody Drug Conjugate (ADC)
Chimeric Antigen Receptor (CAR) T cell
Dicer Substrate siRNA
Other Therapeutic tools
Diagnostic

Discovery

Pancreatic Cancer
Colorectal
Ovarian Cancer
Metastatic Tumors

Preclinical

Pancreatic Cancer
Colorectal
Ovarian

NEWS

Patent & Platform

KAHF Biotech Announces Expansion of Its Patent-Pending Oncology Platform

KAHF Biotech continues to advance its target-centric therapeutic ecosystem focused on addressing cancer progression, metastasis, treatment resistance, and tumor recurrence. The platform supports the development of multiple therapeutic modalities, including monoclonal antibodies, antibody-drug conjugates (ADCs), CAR-T cells, T cell engager, RNA therapeutics, and precision oncology applications across diverse solid and hematological malignancies.

Date: May 2026Read More »

Research Progress

KAHF Biotech Reports Continued Progress in Preclinical Research

KAHF Biotech is advancing preclinical studies of novel monoclonal antibody candidates targeting pathways involved in tumor progression and metastatic disease. Ongoing research includes proof-of-concept, efficacy, mechanism-of-action, and initial safety evaluations to support the continued development of next-generation oncology therapeutics.

Date: June 2026Read More »

Collaborations

KAHF Biotech Expands Scientific and Strategic Collaborations

KAHF Biotech continues to strengthen collaborations with academic institutions, scientific advisors, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs) to support the advancement of its next-generation oncology pipeline and platform technologies.

Date: June 2026Read More »